tebu-bio recently signed an agreement with Enzium Inc. (Philadelphia, PA, USA) for the distribution in 
Europe of their protease activity assays.
Enzium has developed a new approach to measure the activity of proteases such as diverse MMPs, ADAMs, Thrombin, Factor Xa, and Furin and the inhibitory effects of drug candidates.
Dr. Diana Hulboy (VP, Marketing and Business Development at Enzium) says: “We are thrilled to collaborate with tebu-bio on the marketing of EnSens® assays throughout the European community, as we believe our new, non-FRET fluorescent technology will change how researchers think about protease activity detection.”
Dr. Ali El Bayâ (tebu-bio, Sales Manager – Proteins & Protein based Products & Services) adds “Enzium’s EnSens® technology is a very promising alternative to classical FRET based protease assays which are used in screenings in drug discovery. The benefits of this new approach in terms of lower signal to noise ratio and higher flexibility in creating longer and more complex protease recognition sites seem obvious to us. We are sure our extensive customer base within the drug discovery community will be keen to use this technology.”
Contact your local tebu-bio office to discuss further about your protease assays.
